A Phase II Study in Infants (Greater Than or Equal to 6 - Less Than 36 Months), Children (Greater Than or Equal to 36 Months - 9 Years) and Adolescents (10 - 17 Years) to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Administered at Two Dose Levels.
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 15 Apr 2013 ID N01AI80057C deleted - not a trial-specific identifier.
- 24 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jun 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.